autologous CD133

Autologous CD133 refers to therapeutic cells isolated from a patient's own tissue (commonly bone marrow), selected for expression of the CD133 surface marker (also known as Prominin-1). CD133 is a pentaspan transmembrane glycoprotein expressed by stem and progenitor cells, and is implicated in both regenerative medicine and oncology. In regenerative contexts, autologous CD133+ cells are used for their pluripotent and angiogenic capacity to promote tissue repair, neovascularization, inhibition of apoptosis, and overall functional recovery (such as post-cardiac ischemia or bone necrosis)[4][6][5]. In oncology, therapies include autologous chimeric antigen receptor T cells (CAR-T) or dendritic cells engineered to target CD133+ cancer stem cells, aiming to eradicate cancer cells that drive tumorigenesis and recurrence[1][2][3]. The mechanism is disease-dependent: as a cell therapy, direct incorporation following transplantation can contribute to tissue healing, while as modified immunotherapy (CAR-T or antigen-loaded dendritic cells), it exerts targeted cytotoxic or immune-priming effects against CD133+ cells.

Other names

autologous CD133+ stem cellsautologous bone marrow-derived CD133+ cellsautologous CD133+ cells